These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 32054838)

  • 1. A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity.
    Nelson L; Tighe A; Golder A; Littler S; Bakker B; Moralli D; Murtuza Baker S; Donaldson IJ; Spierings DCJ; Wardenaar R; Neale B; Burghel GJ; Winter-Roach B; Edmondson R; Clamp AR; Jayson GC; Desai S; Green CM; Hayes A; Foijer F; Morgan RD; Taylor SS
    Nat Commun; 2020 Feb; 11(1):822. PubMed ID: 32054838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
    Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
    Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instability.
    Nelson L; Barnes BM; Tighe A; Littler S; Coulson-Gilmer C; Golder A; Desai S; Morgan RD; McGrail JC; Taylor SS
    Chromosome Res; 2023 Aug; 31(3):21. PubMed ID: 37592171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8.
    Tudrej P; Olbryt M; Zembala-Nożyńska E; Kujawa KA; Cortez AJ; Fiszer-Kierzkowska A; Pigłowski W; Nikiel B; Głowala-Kosińska M; Bartkowska-Chrobok A; Smagur A; Fidyk W; Lisowska KM
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples.
    Penner-Goeke S; Lichtensztejn Z; Neufeld M; Ali JL; Altman AD; Nachtigal MW; McManus KJ
    PLoS Genet; 2017 Apr; 13(4):e1006707. PubMed ID: 28376088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Profiles Associated with Chemoresistance in Patient-Derived Xenograft Models of Ovarian Cancer.
    Li LY; Kim HJ; Park SA; Lee SH; Kim LK; Lee JY; Kim S; Kim YT; Kim SW; Nam EJ
    Cancer Res Treat; 2019 Jul; 51(3):1117-1127. PubMed ID: 30428638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
    Morden CR; Farrell AC; Sliwowski M; Lichtensztejn Z; Altman AD; Nachtigal MW; McManus KJ
    Gynecol Oncol; 2021 Jun; 161(3):769-778. PubMed ID: 33714608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability.
    Raab M; Sanhaji M; Zhou S; Rödel F; El-Balat A; Becker S; Strebhardt K
    Neoplasia; 2019 Apr; 21(4):363-375. PubMed ID: 30851646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer.
    Zhang M; Zhuang G; Sun X; Shen Y; Wang W; Li Q; Di W
    Diagn Pathol; 2017 Feb; 12(1):16. PubMed ID: 28148293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
    Fransson Å; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N
    J Ovarian Res; 2016 May; 9(1):27. PubMed ID: 27179933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer.
    Raab M; Kostova I; Peña-Llopis S; Fietz D; Kressin M; Aberoumandi SM; Ullrich E; Becker S; Sanhaji M; Strebhardt K
    Cancer Commun (Lond); 2024 Jan; 44(1):101-126. PubMed ID: 38140698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific Mechanisms of Chromosomal Instability Indicate Therapeutic Sensitivities in High-Grade Serous Ovarian Carcinoma.
    Tamura N; Shaikh N; Muliaditan D; Soliman TN; McGuinness JR; Maniati E; Moralli D; Durin MA; Green CM; Balkwill FR; Wang J; Curtius K; McClelland SE
    Cancer Res; 2020 Nov; 80(22):4946-4959. PubMed ID: 32998996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
    Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
    Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
    Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
    Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
    Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
    Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ongoing chromosomal instability and karyotype evolution in human colorectal cancer organoids.
    Bolhaqueiro ACF; Ponsioen B; Bakker B; Klaasen SJ; Kucukkose E; van Jaarsveld RH; Vivié J; Verlaan-Klink I; Hami N; Spierings DCJ; Sasaki N; Dutta D; Boj SF; Vries RGJ; Lansdorp PM; van de Wetering M; van Oudenaarden A; Clevers H; Kranenburg O; Foijer F; Snippert HJG; Kops GJPL
    Nat Genet; 2019 May; 51(5):824-834. PubMed ID: 31036964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.
    Seagle BL; Yang CP; Eng KH; Dandapani M; Odunsi-Akanji O; Goldberg GL; Odunsi K; Horwitz SB; Shahabi S
    Gynecol Oncol; 2015 Jul; 138(1):159-64. PubMed ID: 25958320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
    Mota A; Triviño JC; Rojo-Sebastian A; Martínez-Ramírez Á; Chiva L; González-Martín A; Garcia JF; Garcia-Sanz P; Moreno-Bueno G
    BMC Cancer; 2015 Nov; 15():940. PubMed ID: 26620706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2D-WDFY2 is a cancer-specific fusion gene recurrent in high-grade serous ovarian carcinoma.
    Kannan K; Coarfa C; Rajapakshe K; Hawkins SM; Matzuk MM; Milosavljevic A; Yen L
    PLoS Genet; 2014 Mar; 10(3):e1004216. PubMed ID: 24675677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.